Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10652292 | 0.75 | MAP4K4 (0.36) | ABCG2KMT2ADYRK1BMAPTMAPK1 | |
| SCHEMBL451749 | 0.75 | DYRK1A (0.38) | ABCG2EGFRCYP2A6HTTKMT2A | |
| SCHEMBL22400521 | 0.75 | MEN1 (0.37) | ABCG2EGFRCYP2A6HTTKMT2A | |
| SCHEMBL12483324 | 0.75 | CCR1 (0.48) | ABCG2CYP2A6ALDH1A1NOS1KDM4E | |
| SCHEMBL4486974 | 0.75 | ABCG2 (0.39) | ABCG2EGFRHTTSMN1; SMN2RAB9A | |
| SCHEMBL24565560 | 0.75 | ABCG2 (0.34) | ABCG2DYRK1BDYRK1ACHEK1AURKA | |
| SCHEMBL844341 | 0.71 | HPGDS (0.41) | ABCG2HTTKMT2ADYRK1BALDH1A1 | |
| SCHEMBL10851948 | 0.71 | ABCG2 (0.42) | ABCG2EGFRKMT2ARAB9ANPC1 | |
| SCHEMBL25054255 | 0.71 | CYP2A6 (0.55) | ABCG2CYP2A6DYRK1BDYRK1ACHEK1 | |
| SCHEMBL19436087 | 0.71 | CYP2A6 (0.50) | ABCG2CYP2A6RAB9ADYRK1BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457333-A | Organic solar cell receptor material and preparation method thereof | 黄培钧 | 2021-03-09 | — | — | CN | claimed |
| EP-4709481-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| US-12410194-B2 | Potent and selective azaindole inhibitors of CDK8 and CDK19 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20240409557-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024233550-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240307547-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-19 | — | — | US | disclosed |
| EP-4271670-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2023-11-08 | — | — | EP | disclosed |
| CN-116917275-A | Novel CEREBLON-binding compounds and methods of use thereof | 凯普托尔治疗学股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230242556-A1 | NOVEL METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND | SFC CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | DART MICHAEL J | 2006-12-21 | — | — | US | disclosed |
| US-7135484-B2 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060148730-A1 | Using macrolide and ketolide compound | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-07-06 | — | — | US | disclosed |
| EP-1539733-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005007143-A2 | USE OF MAKROLIDES AND KETOLIDES FOR THE TREATMENT OF TUBERCULOSIS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014706-A1 | Method of treating tuberculosis | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2005-01-20 | — | — | US | disclosed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
| WO-2004016604-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | ABCG2 96/4885EGFR 2772/4885CYP2A6 27/4885 |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | ABCG2 3008/4885EGFR 4664/4885CYP2A6 270/4885 |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | ABCG2 3008/4885EGFR 4664/4885CYP2A6 270/4885 |
| US-20060148730-A1 | Using macrolide and ketolide compound | MLYCD, TREH, TKT | ABCG2 1926/4885EGFR 4487/4885CYP2A6 1095/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ABCG2 960/4885EGFR 3271/4885CYP2A6 2398/4885 |
| US-20240409557-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | HPGD, ADH1A, ADH5 | ABCG2 2782/4885EGFR 3645/4885CYP2A6 13/4885 |
| US-20230242556-A1 | NOVEL METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND | BCL6B, BRD7, DBF4 | ABCG2 1331/4885EGFR 3636/4885CYP2A6 1832/4885 |
| US-12410194-B2 | Potent and selective azaindole inhibitors of CDK8 and CDK19 | CDK8, CDK9, CDK19 | ABCG2 2619/4885EGFR 2752/4885CYP2A6 3758/4885 |
| US-20050014706-A1 | Method of treating tuberculosis | TREH, TKT, DCXR | ABCG2 2783/4885EGFR 4535/4885CYP2A6 924/4885 |
| US-20240307547-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | ABCG2 113/4885EGFR 3394/4885CYP2A6 3765/4885 |
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHAT, CHRNA6 | ABCG2 2597/4885EGFR 4720/4885CYP2A6 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.